Your Patients Can't Find Clorazepate — Here's How You Can Help

When a patient on Clorazepate (Tranxene) calls your office saying they can't fill their prescription, it's more than an inconvenience — it's a clinical risk. Abrupt benzodiazepine discontinuation can trigger withdrawal seizures, rebound anxiety, and autonomic instability. As a prescriber, you're in a unique position to help navigate the availability challenge and ensure continuity of care.

This guide provides actionable steps your practice can take when Clorazepate supply runs into obstacles.

Current Availability Landscape

Clorazepate Dipotassium is a long-acting benzodiazepine (Schedule IV) available in 3.75 mg, 7.5 mg, and 15 mg oral tablets. While not listed on the FDA Drug Shortage Database, it faces persistent real-world availability challenges:

• Limited manufacturer base: Brand Tranxene is produced by Recordati Rare Diseases Inc. Generic production has historically been limited to a small number of companies, though ANI Pharmaceuticals gained FDA approval for a new generic in early 2026.
• Low stocking priority: Chain pharmacies often don't routinely stock Clorazepate because prescribing volume is low compared to Alprazolam, Lorazepam, or Clonazepam.
• Controlled substance logistics: DEA quotas and reporting requirements add friction to ordering and restocking, particularly for lower-volume medications.

Why Patients Can't Find It

Understanding the bottleneck helps you guide patients more effectively:

1. Their pharmacy doesn't stock it: This is the most common scenario. The pharmacy physically does not have Clorazepate on the shelf and may not have an active wholesale relationship for it.
2. Wholesaler is backordered: Even when a pharmacy tries to order Clorazepate, their primary wholesaler may not have it available for immediate shipment.
3. Prescription routing issues: E-prescriptions sent to pharmacies that don't carry the drug create unnecessary delays. Knowing which pharmacies stock it before sending the prescription saves time.

What Providers Can Do: 5 Actionable Steps

Step 1: Direct Patients to Medfinder

Medfinder for Providers is a free tool that shows real-time pharmacy availability by medication and location. Instead of asking patients to cold-call pharmacies, direct them to Medfinder to identify pharmacies that currently have Clorazepate in stock.

Consider printing the URL or including it in patient after-visit instructions for any patient on a medication with known availability issues.

Step 2: Send Prescriptions to Pharmacies That Stock It

Once you know which pharmacies have Clorazepate (via Medfinder or direct outreach), route prescriptions accordingly. This is especially important for new prescriptions or transfers — sending to a pharmacy that stocks the drug eliminates the most common delay.

Step 3: Call the Pharmacy Directly

A prescriber-to-pharmacist call carries significant weight. Pharmacists can often expedite special orders or check secondary wholesalers when prompted by a prescriber. Your call signals clinical urgency and can move the process forward faster than a patient call alone.

Step 4: Designate a Staff Point Person

For practices that prescribe Clorazepate or other medications with known supply challenges, consider designating a medical assistant or nurse to manage medication availability inquiries. This person can:

• Check Medfinder proactively before sending prescriptions
• Maintain a list of pharmacies known to stock Clorazepate
• Follow up on pending fills and transfers
• Escalate to the prescriber when alternatives are needed

Step 5: Have an Alternative Protocol Ready

When Clorazepate is genuinely unavailable, having a pre-planned switching protocol saves valuable clinical time. Recommended alternatives by indication:

For anxiety:

• Diazepam (Valium) — closest pharmacologic match; 7.5 mg Clorazepate ≈ 5 mg Diazepam
• Lorazepam (Ativan) — shorter acting but widely available; 7.5 mg Clorazepate ≈ 0.5-1 mg Lorazepam
• Non-benzodiazepine options: Buspirone, SSRIs, or SNRIs for long-term anxiety management

For partial seizures (adjunctive):

• Clonazepam (Klonopin) — strong anticonvulsant profile; 7.5 mg Clorazepate ≈ 0.25-0.5 mg Clonazepam
• Clobazam (Onfi) — FDA-approved for Lennox-Gastaut syndrome, used more broadly for epilepsy

For alcohol withdrawal:

• Chlordiazepoxide (Librium) — long-acting, traditional first-line for CIWA-based protocols
• Diazepam — effective with predictable pharmacokinetics for withdrawal management
• Lorazepam — preferred in hepatic impairment (glucuronidation, no active metabolites)

Workflow Tips for Your Practice

• Flag Clorazepate patients in your EHR: Add a note or flag to patient charts indicating they take a medication with known supply challenges. This prompts proactive check-ins at visits.
• Encourage early refills: Advise patients to request refills 7-10 days before running out. Document this recommendation in the plan.
• Document availability-driven switches: When you change a patient's medication due to supply rather than clinical preference, document the reason explicitly. This protects the patient's clinical narrative and supports any insurance appeals.
• Keep a pharmacy resource list: Maintain an updated list of local pharmacies that reliably stock Clorazepate. Share this with front desk and nursing staff.

Final Thoughts

Medication availability challenges are an increasingly common part of clinical practice, and Clorazepate is a particularly important example because of the clinical risks of abrupt discontinuation. By integrating availability tools like Medfinder into your workflow, maintaining switching protocols, and proactively communicating with pharmacies, you can significantly reduce the burden on your patients and your practice.

For the broader supply picture, see our companion briefing: Clorazepate shortage — what providers need to know in 2026. To share with patients who are struggling with cost, point them to how to save money on Clorazepate.